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Exploring the role of versican and its regulation by microRNA in Multiple Myeloma  
 
 
The abnormal growth of malignant plasma cells in Multiple Myeloma (MM) require bone 
marrow (BM) niche consisting of proteoglycans, cytokines, etc. Versican (VCAN), a chondroitin 
sulfate proteoglycan promote progression in solid tumors but there is dearth of literature in MM. 
Hence, we studied the involvement of VCAN in MM and its regulation by microRNAs as a 
therapeutic approach. 30 MM patients and 20 controls were recruited and BM Stromal Cells 
(BMSCs) were isolated by primary culture. Molecular levels of VCAN, miR-144, miR-199 & 
miR-203 were examined in study subjects and cell lines. The involvement of VCAN in myeloma 
pathogenesis was studied using BMSCs-conditioned medium (BMSCs-CM) and recombinant 
versican G3 domain. The regulation of versican was studied by microRNA mimics and inhibitors. 
Elevated expression of VCAN was observed in patients especially in bone marrow stroma while 
microRNA expression was significantly lower and showed negative correlation with VCAN. 
Moreover, BMSCs-CM showed presence of VCAN which upon supplementing to MM cells alter 
parameters in favour of myeloma progression, however, this effect was neutralized by VCAN 
antibody. The downstream signaling of VCAN was found to activate FAK and STAT3 which 
subsides by using VCAN antibody. The recombinant VCAN spanning G3 domain also leads to 
the alteration in cancer hallmarks in favor of myeloma pathogenesis with downstream activation 
of FAK and STAT3 signaling. The transfection of microRNA mimics (miR-144 and miR-199) 
in primary BMSCs leads to the significant knockdown of transcript and protein levels of VCAN. 
The inclusion of microRNA mimics transfected BMSCs-CM reversed the pro-myeloma effect of 
BMSCs-CM in the myeloma cells. The microRNA mediated knockdown of VCAN interferes 
with the paracrine signaling of VCAN and impede the activation of FAK and STAT3 signaling 
in myeloma cells. The regulation of VCAN by microRNAs was also studied by transfecting 
microRNAs inhibitors to myeloma cell lines. Inhibition of microRNAs by anti-miR oligos in 
myeloma cells resulted in significant over-expression of VCAN. The microRNA antagomirs 
mediated upregulation of VCAN observed to contribute in myeloma pathogenesis with 
downstream activation of FAK and STAT3 signaling. Thus, VCAN was observed as a paracrine 
mediator in the cross-talk of BMSCs and myeloma cells in BM microenvironment which could 
be regulated by miR-144 and miR-199. Therefore, these findings suggest exploring VCAN as 
novel therapeutic target and utilization of microRNAs as therapy to regulate VCAN for better 
management of MM.  
 
